All registered trademarks are the property of their respective owners.
President, Founder, and Chief Executive Officer: Erik C. Emerson
Erik Emerson is a 15-year veteran of the pharmaceutical industry with an expansive background in sales and marketing. Most recently, Mr. Emerson worked as the Head of Commercial Development for XOMA (US) LLC, where he led multiple business and commercial development deals and was responsible for building commercial infrastructure for XOMA’s first and only commercial product in its 32-year history. Mr. Emerson began his career in field sales for King Pharmaceuticals before transitioning to sales training. Mr. Emerson moved from Training into Marketing as a member of the Altace® (ramipril) capsules brand team, from there he led the transition of Altace marketing back to King Pharmaceuticals upon dissolution of the co-promote agreement with Wyeth.
Mr. Emerson advanced his commercial career with a move to Gilead Sciences. At Gilead he was responsible for physician promotions during the launch of Letairis® (ambrisentan). During his time at Gilead, Mr. Emerson launched multiple initiatives, including a unique program called LabSync®, designed to streamline ordering and tracking of laboratory work on behalf of physician offices and patients.
Sr. VP, Founder, and Chief Medical Officer: Jeff Feldstein, MD, FAAFP
Dr. Jeff Feldstein, a graduate of Rush Medical College and Fellow of the American Academy of Family Physicians, was medical director of Chicago HMO. In 2000, he joined the Sanofi-Organon LLC to launch ARIXTRA® (fondaparinux sodium) solution, the first synthetic factor Xa inhibitor. Dr. Feldstein joined Novartis specifically to take part in the Diovan® (valsartan tablets) pediatric trial. He also was involved in development of TEKTURNA® (aliskiren) tablets, Exforge® (amlodipine and valsartan) tablets, and Exforge HCT® (amlodipine, valsartan, hydrochlorothiazide) tablets. During his tenure with Novartis, Dr. Feldstein was responsible for Diovan Medical Affairs in the United States. Upon leaving Novartis, Dr. Feldstein joined King Pharmaceuticals, serving as Director of Medical Affairs for their $2 billion portfolio. Following which, he was a principal in the IMS Health strategic intelligence group.
At XOMA, Dr. Feldstein led the cardiometabolic development of gevokizumab. He was also integral in structuring agreements to bring the perindopril franchise back to the United States through XOMA, and in subsequently working with Mr. Emerson to transition the franchise to the newly formed company, symplmed.
Board of Directors
August J. Troendle, MD, President and CEO, Medpace, Inc.
Erik C. Emerson, President and CEO, Symplmed Pharmaceuticals
Jesse J. Geiger, CPA, Vice President, Chief Financial Officer and Treasurer, Medpace. Inc.
Stephen P. Ewald, JD, General Counsel, Medpace. Inc.
R. Blane Walter, Partner, Talisman Capital Partners and Vice Chairman, inVentiv Health
Register for updates to be alerted when new information is available.